Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Buy
58
TNXP Quote, Financials, Valuation and Earnings
Last price:
$29.74
Seasonality move
:
-16.53%
Day range:
$26.55 - $37.83
52-week range:
$6.76 - $1,146.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.83x
P/B ratio:
1.41x
Volume:
7.4M
Avg. volume:
1.8M
1-year change:
-97.24%
Market cap:
$196.3M
Revenue:
$10.1M
EPS (TTM):
-$2,536.77
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$3.4M | -$2.68 | 4.75% | -99.46% | $406.67 |
|
CGTX
Cognition Therapeutics
|
-- | -$0.15 | -- | -57.41% | $5.40 |
|
COCP
Cocrystal Pharma
|
-- | -$0.53 | -- | -46.15% | $8.33 |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
PDSB
PDS Biotechnology
|
-- | -$0.28 | -- | -7.62% | $10.13 |
|
RAFA
Rafarma Pharmaceuticals
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$30.51 | $406.67 | $196.3M | -- | $0.00 | 0% | 3.83x |
|
CGTX
Cognition Therapeutics
|
$0.49 | $5.40 | $30.4M | -- | $0.00 | 0% | -- |
|
COCP
Cocrystal Pharma
|
$1.58 | $8.33 | $16.1M | -- | $0.00 | 0% | 7.99x |
|
NBY
NovaBay Pharmaceuticals
|
$0.62 | $0.85 | $3M | -- | $0.00 | 0% | 0.07x |
|
PDSB
PDS Biotechnology
|
$1.37 | $10.13 | $51.3M | -- | $0.00 | 0% | -- |
|
RAFA
Rafarma Pharmaceuticals
|
$0.1282 | -- | $10.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
5.09% | -2.308 | 5.18% | 5.84x |
|
CGTX
Cognition Therapeutics
|
-- | -3.565 | -- | -- |
|
COCP
Cocrystal Pharma
|
-- | 2.120 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.646 | 1.51% | 0.75x |
|
PDSB
PDS Biotechnology
|
-- | 0.230 | -- | -- |
|
RAFA
Rafarma Pharmaceuticals
|
-- | -5.010 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding
|
$1.4M | -$21.6M | -127.14% | -138.47% | -834.78% | -$14.6M |
|
CGTX
Cognition Therapeutics
|
-- | -$7.7M | -- | -- | -- | -$8.4M |
|
COCP
Cocrystal Pharma
|
-- | -$5M | -- | -- | -- | -$5.1M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PDSB
PDS Biotechnology
|
-- | -$10.2M | -- | -- | -- | -$8M |
|
RAFA
Rafarma Pharmaceuticals
|
-- | -- | -- | -- | -- | -- |
Tonix Pharmaceuticals Holding vs. Competitors
-
Which has Higher Returns TNXP or CGTX?
Cognition Therapeutics has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Cognition Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding54.18% -$9.77 $147M CGTXCognition Therapeutics-- -$0.17 -- -
What do Analysts Say About TNXP or CGTX?
Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1232.9%. On the other hand Cognition Therapeutics has an analysts' consensus of $5.40 which suggests that it could grow by 1002.49%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Cognition Therapeutics, analysts believe Tonix Pharmaceuticals Holding is more attractive than Cognition Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 CGTXCognition Therapeutics4 0 0 -
Is TNXP or CGTX More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison Cognition Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TNXP or CGTX?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cognition Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cognition Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or CGTX?
Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Cognition Therapeutics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than Cognition Therapeutics's net income of -$7.8M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cognition Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 3.83x versus -- for Cognition Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding3.83x -- $2.6M -$22.1M CGTXCognition Therapeutics-- -- -- -$7.8M
-
Which has Higher Returns TNXP or COCP?
Cocrystal Pharma has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Cocrystal Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding54.18% -$9.77 $147M COCPCocrystal Pharma-- -$0.49 -- -
What do Analysts Say About TNXP or COCP?
Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1232.9%. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 427.43%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Cocrystal Pharma, analysts believe Tonix Pharmaceuticals Holding is more attractive than Cocrystal Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 COCPCocrystal Pharma1 0 0 -
Is TNXP or COCP More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.347, suggesting its more volatile than the S&P 500 by 134.714%.
-
Which is a Better Dividend Stock TNXP or COCP?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or COCP?
Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Cocrystal Pharma quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than Cocrystal Pharma's net income of -$4.9M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 3.83x versus 7.99x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding3.83x -- $2.6M -$22.1M COCPCocrystal Pharma7.99x -- -- -$4.9M
-
Which has Higher Returns TNXP or NBY?
NovaBay Pharmaceuticals has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of -49.65%. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding54.18% -$9.77 $147M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About TNXP or NBY?
Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1232.9%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 37.1%. Given that Tonix Pharmaceuticals Holding has higher upside potential than NovaBay Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is TNXP or NBY More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.
-
Which is a Better Dividend Stock TNXP or NBY?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or NBY?
Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 3.83x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding3.83x -- $2.6M -$22.1M NBYNovaBay Pharmaceuticals0.07x -- $2.4M -$1.2M
-
Which has Higher Returns TNXP or PDSB?
PDS Biotechnology has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat PDS Biotechnology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding54.18% -$9.77 $147M PDSBPDS Biotechnology-- -$0.29 -- -
What do Analysts Say About TNXP or PDSB?
Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1232.9%. On the other hand PDS Biotechnology has an analysts' consensus of $10.13 which suggests that it could grow by 639.05%. Given that Tonix Pharmaceuticals Holding has higher upside potential than PDS Biotechnology, analysts believe Tonix Pharmaceuticals Holding is more attractive than PDS Biotechnology.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 PDSBPDS Biotechnology3 0 0 -
Is TNXP or PDSB More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison PDS Biotechnology has a beta of 1.676, suggesting its more volatile than the S&P 500 by 67.622%.
-
Which is a Better Dividend Stock TNXP or PDSB?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. PDS Biotechnology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or PDSB?
Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than PDS Biotechnology quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than PDS Biotechnology's net income of -$10.7M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while PDS Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 3.83x versus -- for PDS Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding3.83x -- $2.6M -$22.1M PDSBPDS Biotechnology-- -- -- -$10.7M
-
Which has Higher Returns TNXP or RAFA?
Rafarma Pharmaceuticals has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Rafarma Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNXPTonix Pharmaceuticals Holding54.18% -$9.77 $147M RAFARafarma Pharmaceuticals-- -- -- -
What do Analysts Say About TNXP or RAFA?
Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1232.9%. On the other hand Rafarma Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Tonix Pharmaceuticals Holding has higher upside potential than Rafarma Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than Rafarma Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings TNXPTonix Pharmaceuticals Holding2 0 0 RAFARafarma Pharmaceuticals0 0 0 -
Is TNXP or RAFA More Risky?
Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison Rafarma Pharmaceuticals has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.411%.
-
Which is a Better Dividend Stock TNXP or RAFA?
Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rafarma Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Rafarma Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNXP or RAFA?
Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Rafarma Pharmaceuticals quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is higher than Rafarma Pharmaceuticals's net income of --. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Rafarma Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 3.83x versus -- for Rafarma Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNXPTonix Pharmaceuticals Holding3.83x -- $2.6M -$22.1M RAFARafarma Pharmaceuticals-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Why Did StoneCo Stock Go Up So Much?
Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is up 4.9% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 1.01% over the past day.
Sell
36
MPTI alert for Mar 25
M-Tron Industries [MPTI] is up 7.48% over the past day.
